Ep. 309 - 3Q Markets Preview; Quantum Computing; Makary’s First 100 Days

Chinese biotech is the lone bright spot for the biopharma financial markets in 1H25, as macro concerns about the most favored nation (MFN) pricing policy and FDA weigh on the prospects for biotech elsewhere. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the positives — and negatives — impacting investor sentiment headed into the second half of the year. The team also discuss where the quantum computing revolution could have its biggest impact on drug development, and review the proposals and accomplishments of FDA Commissioner Marty Makary over his first 100 days in office. This episode of BioCentury This Week was sponsored by IQVIA Biotech.View full story: https://www.biocentury.com/article/656482#biotech #biopharma #pharma #lifescience #financialmarkets #FDA #quantumcomputing00:01 - Sponsor Message: IQVIA Biotech04:43 - Q25 Financial Markets Preview22:20 - Quantum Computing Impact on Biopharma30:07 - Makary's First 100 DaysTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text

There are no comments yet.

Please log in to write the first comment.